Adult Sprague Dawley rats received MCOPPB by intraperitoneal injection after coronary artery ligation. Ejection fraction significantly improved with MCOPPB compared with saline at euthanasia. In CD-1 mice, intraperitoneal MCOPPB before formalin injection produced dose-dependent antinociceptive effects during the second phase compared with vehicle. [1,2]
MCOPPB and ejection fraction after coronary artery ligation
Animal study · Adult Sprague Dawley rats [1]
Adult Sprague Dawley rats received MCOPPB by intraperitoneal injection after coronary artery ligation. Ejection fraction significantly improved with MCOPPB compared with saline at euthanasia.
Conditions shared by the study groups
- Route
- intraperitoneal injection
- Treatment course
- Three weeks after the coronary artery ligation, normal saline or MCOPPB (2.5 mg/kg/day) intraperitoneal injection was started, and continued 5 days per week for 3 months
- Vehicle
- normal saline
- MCOPPB 2.5 mg/kg/day
- Model: Adult Sprague Dawley rats
Methods and source locations
Compound reported in the paper: MCOPPB
The paper names MCOPPB without stating the salt or form; not verified as the trihydrochloride form supplied as A10561. No dose conversion or lot validation.
2. Materials and Methods > 2.1. Animals (S4, S6, S9); 2. Materials and Methods > 2.2. ORL1 Activator (S17); 2. Materials and Methods > 2.3. Treatment (S20); 3. Results > 3.1. In Vivo Experiments (S50)
ejection fraction: ejection fraction; comparator: saline — 3. Results > 3.1. In Vivo Experiments (S50)
MCOPPB 2.5 mg/kg/day · 2. Materials and Methods > 2.3. Treatment (S20); 3. Results > 3.1. In Vivo Experiments (S50)
MCOPPB and formalin-induced pain behavior
Animal study · CD-1 mice; 8 mice/group [2]
CD-1 mice received MCOPPB at 10 mg/kg i.p. before formalin injection. MCOPPB produced dose-dependent antinociceptive effects compared with vehicle, with effects reported during the second phase.
Conditions shared by the study groups
- Route
- i.p.
- Treatment course
- 30 min before formalin injection; during 15–45 min
- Vehicle
- water containing 1% DMSO and 0.3% cyclodextrin
- MCOPPB 10 mg/kg
- Model: CD-1 mice; 8 mice/group
- Reported limits: Removed after verification: value.
Methods and source locations
Compound reported in the paper: MCOPPB
Evidence for MCOPPB as the hydrate, trihydrochloride form reported in the paper, not the trihydrochloride form supplied as A10561; no salt equivalence, dose conversion or lot validation.
Materials and Methods > Drugs (S4); Materials and Methods > Formalin Test (S44, S47, S48); Materials and Methods > Data Analysis (S58); Results > Antinociceptive and Locomotor Impairing Effects of MCOPPB, Ro-656570, and AT-403 (S83); FIGURE 6 legend (S109, S110, S111, S112); FIGURE 7 legend (S115); TABLE 1 legend (S118); TABLE 1 (T1.h1, T1.r2)
Cumulative formalin–induced pain behavior during the I° and II° phases; second phase: Cumulative formalin–induced pain behavior during the I° and II° phases; second phase; comparator: vehicle treated animals — Results > Antinociceptive and Locomotor Impairing Effects of MCOPPB, Ro-656570, and AT-403 (S83); FIGURE 6 legend (S110); FIGURE 7 legend (S115); TABLE 1 legend (S118); TABLE 1 (T1.h1, T1.r2)
MCOPPB 10 mg/kg · Materials and Methods > Formalin Test (S47, S48); Results > Antinociceptive and Locomotor Impairing Effects of MCOPPB, Ro-656570, and AT-403 (S83); TABLE 1 legend (S118); TABLE 1 (T1.h1, T1.r2)